Technical Analysis for CCXI - ChemoCentryx, Inc.

Grade Last Price % Change Price Change
grade A 12.45 0.48% 0.06
CCXI closed up 1.39 percent on Thursday, January 17, 2019, on 2.62 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical CCXI trend table...

Date Alert Name Type % Chg
Jan 17 Pocket Pivot Bullish Swing Setup 0.48%
Jan 17 Inside Day Range Contraction 0.48%
Jan 17 Wide Bands Range Expansion 0.48%
Jan 17 Overbought Stochastic Strength 0.48%
Jan 16 Shooting Star Candlestick Bearish 1.88%
Jan 16 Wide Bands Range Expansion 1.88%
Jan 16 Overbought Stochastic Strength 1.88%
Jan 15 180 Bullish Setup Bullish Swing Setup 2.55%
Jan 15 Wide Bands Range Expansion 2.55%
Jan 15 Overbought Stochastic Strength 2.55%

Older signals for CCXI ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. Its drug candidates under clinical stage include Vercirnon, which is in Phase III clinical trials for the treatment of patients with moderate-to-severe Crohn's disease; CCX140 that is in Phase II clinical trials for the treatment of patients with diabetic nephropathy, a form of kidney disease; and CCX354 that completed a Phase II proof-of-concept clinical trial for the treatment of rheumatoid arthritis. The company's drug candidates also comprise CCX168, which is in a Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody associated vasculitis; CCX872 that is under Phase I clinical development targeting CCR2 for expanded indications of renal disease; and CCX507, a de novo wholly-owned CCR9 inhibitor, which is in Phase I clinical trials for inflammatory bowel disease and related disorders. Its preclinical stage programs comprise CCX650, an orally active drug for the treatment of glioblastoma multiforme; CCR4 inhibitor for atopic dermatitis; CCX6239, an orally administered CCR4 antagonist with potential utility in the treatment of atopic dermatitis, an inflammatory disease; CCR6 inhibitor for autoimmune diseases; and CXCR6 inhibitor for chronic hepatitis. ChemoCentryx, Inc. has a strategic alliance with Glaxo Group Limited for the discovery and development of small molecule antagonists targeting four defined chemokine and chemo-attractant receptor targets and for advancing them through clinical proof-of-concept. The company was founded in 1997 and is headquartered in Mountain View, California.
Is CCXI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 15.08
52 Week Low 8.2
Average Volume 223,963
200-Day Moving Average 11.5393
50-Day Moving Average 10.6296
20-Day Moving Average 11.318
10-Day Moving Average 12.11
Average True Range 0.5265
ADX 34.11
+DI 28.4999
-DI 10.8884
Chandelier Exit (Long, 3 ATRs ) 11.0205
Chandelier Exit (Short, 3 ATRs ) 11.0195
Upper Bollinger Band 13.076
Lower Bollinger Band 9.56
Percent B (%b) 0.8
BandWidth 31.065559
MACD Line 0.5351
MACD Signal Line 0.4469
MACD Histogram 0.0883
Fundamentals Value
Market Cap 603.46 Million
Num Shares 48.7 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -19.98
Price-to-Sales 12.42
Price-to-Book 7.97
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.88
Resistance 3 (R3) 12.85 12.66 12.80
Resistance 2 (R2) 12.66 12.53 12.67 12.77
Resistance 1 (R1) 12.52 12.46 12.59 12.55 12.74
Pivot Point 12.33 12.33 12.37 12.35 12.33
Support 1 (S1) 12.20 12.21 12.27 12.23 12.04
Support 2 (S2) 12.01 12.13 12.02 12.01
Support 3 (S3) 11.87 12.01 11.98
Support 4 (S4) 11.90